
Electrocore Announces Inducement Grant Under NASDAQ Listing Rule 5635(C)(4)
About electroCore, Inc.
electroCore, Inc. is a commercial stage bioelectronic technology company whose mission is to improve health and quality of life through innovative non-invasive bioelectronic technologies. The Company's two leading prescription products, gammaCore non-invasive vagus nerve stimulation (nVNS) and Quell neurostimulator, treat chronic pain syndromes through non-invasive neuromodulation technology. Additionally, the company commercializes its handheld, and personal use Truvaga and TAC-STIM nVNS products utilizing bioelectronic technologies to promote general wellness and human performance. For more information, visit .
Contact:
ECOR Investor Relations
(973) 302-9253
...


Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Most popular stories
Market Research

- Financewire And Tipranks Partner To Redefine Financial News Distribution
- Ethereum-Based Defi Crypto Mutuum Finance (MUTM) Reaches 50% Completion In Phase 6
- Stonehaven Circle Marks 13Th Anniversary With Hadrian Colwyn Leading Calvio Ailegacyx Innovation
- Citadel Launches Suiball, The First Sui-Native Hardware Wallet
- Motif AI Enters Phase Two Of Its Growth Cycle
- Dubai At The Centre Of Global Finance: Forex Expo 2025 Redefines The Trading Landscape
Comments
No comment